| Document |
Document Title |
|
WO/2024/078436A1 |
The present disclosure discloses a compound having formula (I) or a pharmaceutically acceptable salt thereof which acts as a USP1 inhibitor, a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt the...
|
|
WO/2024/080330A1 |
The present invention provides a compound having an excellent control effect against harmful arthropods. A compound represented by formula (1) and an N oxide thereof have an excellent control effect against harmful arthropods. [In the fo...
|
|
WO/2024/040109A3 |
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
|
|
WO/2024/078448A1 |
Provided are an HPK1 kinase inhibitor, a preparation method therefor and the use thereof. The kinase inhibitor can adjust (for example, inhibit) HPK1 kinase activity, and thus can be used for treating various HPK1-related diseases includ...
|
|
WO/2024/081318A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/077391A1 |
Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are o...
|
|
WO/2024/081889A1 |
This disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These compounds are useful for treating a disease...
|
|
WO/2024/076989A1 |
The present disclosure relates to chimeric small molecules, which find utility as modifiers of target substrates according to the formula A-L1-E-B or A-L1-E-L2-B, wherein A is a kinase binding moiety; B is a target binding moiety; L1 and...
|
|
WO/2024/076300A1 |
Compounds of the general formula (I) as described and defined herein, in particular compounds of formula (II), methods for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of sa...
|
|
WO/2024/077006A1 |
Described herein are radiotherapeutics that target tumor cells expressing the follicle-stimulating hormone receptor (FSHR) and their use in the treatment and/or diagnosis of cancer.
|
|
WO/2024/074501A1 |
The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.
|
|
WO/2024/075696A1 |
The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc. A compound represented by formula (1) or a pharma...
|
|
WO/2024/067819A1 |
A piperidine-containing polycyclic derivative modulator, a preparation method therefor, and use thereof. In particular, the present invention relates to a compound represented by general formula (II-a), a preparation method therefor, a p...
|
|
WO/2024/069646A1 |
The present invention relates to an improved process for the preparation of Risdiplam compound of Formula-I. The present invention also relates to novel intermediates of Risdiplam compound of Formula-I and process for the preparation of ...
|
|
WO/2024/067793A1 |
Provided in the present disclosure are compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions comprising same, and the use thereof. The compounds are particularly suitable for preparing dru...
|
|
WO/2024/073658A1 |
The subject matter described herein is directed to myelin-promoting compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of admin...
|
|
WO/2024/067820A1 |
Provided are novel tricyclic compounds as CDK inhibitors, which are useful for treating diseases or conditions mediated by CDKs, particularly cancers and other diseases caused by abnormal cell proliferation. Preparation methods, pharmace...
|
|
WO/2024/072793A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/067433A1 |
The present invention describes a novel molecule with inhibitory activity against protein arginine methyltransferase 5 and methods for synthesis and use of the compound. Specifically, the present invention describes a compound of formula...
|
|
WO/2024/067660A1 |
The present disclosure relates to an aza-fused ring compound, a preparation method therefor, and a use thereof in medicine. Specifically, the present disclosure relates to an aza-fused ring compound represented by general formula (I), a ...
|
|
WO/2024/073507A1 |
Described herein are macrocyclic compounds of Formulas (Al), (BI), and (CI) which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a com...
|
|
WO/2024/071398A1 |
The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represe...
|
|
WO/2024/067691A1 |
Disclosed are a nitrogen-containing heterocyclic compound and pharmaceutical use thereof. Specifically, disclosed are a nitrogen-containing heterocyclic compound represented by general formula (I), a preparation method therefor, a pharma...
|
|
WO/2024/072794A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/067575A1 |
Disclosed are a nitrogen-containing polycyclic compound, and a pharmaceutical composition and use thereof. The nitrogen-containing polycyclic compound of the present invention is a nitrogen-containing polycyclic compound represented by f...
|
|
WO/2024/071219A1 |
According to the present invention, a compound represented by formula (I) (wherein, Q (# denotes a bonding site with a sulfur atom, and ● denotes a bonding site with Het) represented in the formula denotes a group or the like represent...
|
|
WO/2024/067845A1 |
An imidazopyridine compound represented by formula (I) as an IRAK4 degradation agent, a tautomer thereof, a stereoisomer thereof, a hydrate thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The...
|
|
WO/2024/073371A1 |
Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
|
|
WO/2024/067714A1 |
The present invention provides compounds having the structure of formula (I) and being capable of being used as a KRAS inhibitor, a pharmaceutical composition comprising the compounds, a method for preparing the compounds, and use of the...
|
|
WO/2024/061370A1 |
Disclosed in the present invention is a pyrimidine-fused ring compound having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof. In addition, further disclosed in the prese...
|
|
WO/2024/064026A1 |
Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
|
|
WO/2024/062871A1 |
The present invention addresses the problem of providing a photoelectric conversion device, an imaging device, a photosensor, and a compound that are excellent with respect to vapor deposition production applicability, electromagnetic st...
|
|
WO/2024/061345A1 |
The present application belongs to the field of medicines, and provides an HPK1 inhibitor, a preparation method therefor, and use thereof. Particularly, disclosed are a compound of formula (I'), a preparation method therefor, a pharmaceu...
|
|
WO/2024/060966A1 |
The present invention relates to a pan-KRAS inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inflam...
|
|
WO/2024/061118A1 |
The present invention provides a macrocyclic nitrogen-containing crown ether compound represented by formula (I) and use thereof as a protein kinase inhibitor.
|
|
WO/2024/061554A1 |
A PARP7 inhibitor compound comprises formula (I), X1 is selected from C, and N. R1, R2, and R3, are each independently H or an organic group. R9 is H or an organic group, or is absent when X1 is N. L is (II). Each R4 is independently sel...
|
|
WO/2024/063143A1 |
The present invention relates to a compound represented by formula (I) or (II) or a pharmaceutically acceptable salt thereof. Formula (I): [wherein: A1 is C(R1), etc.; R1 is a hydrogen atom, etc.; R8 is a hydrogen atom, etc.; B1 is CH,...
|
|
WO/2024/061365A1 |
Provided are a compound represented by formula (I), or a tautomer, a cis-trans isomer, a mesomer, a racemate, an enantiomer, a diastereomer, or an atropisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt, a s...
|
|
WO/2024/064335A1 |
The disclosure provides naphthyl-substituted pyranopyrimidinones and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras activity and their use in the treatment of medical disorders, such as cancer.
|
|
WO/2024/056099A1 |
Provided is use of a compound of formula I, formula I', or formula I", and a tautomer, a stereoisomer, or a pharmaceutically acceptable salt thereof as an METTL3 inhibitor. The compound can be used for treating a condition and a disease ...
|
|
WO/2024/057021A1 |
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
|
|
WO/2024/056090A1 |
Disclosed are a pyrrolopyrimidine derivative as an RSK inhibitor and use thereof. Specifically, disclosed are a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, and use of the compound...
|
|
WO/2024/059808A1 |
Compounds of general Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive ...
|
|
WO/2024/059249A1 |
The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...
|
|
WO/2024/059200A1 |
Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): (I) or a stereoisomer, tautomer, or salt thereof, wherein A, W, X, Y, Z, R1, and R2 are as defined herein. Methods associated with preparatio...
|
|
WO/2024/059845A1 |
A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurolo...
|
|
WO/2024/059558A1 |
The present disclosure relates generally to compounds of Formulae (l-A), (l-B1), (l-C) and ((l-D) and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, method...
|
|
WO/2024/055112A1 |
The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalen...
|
|
WO/2024/051852A1 |
The present invention relates to a pyrimidine-containing polycyclic biological inhibitor, a preparation method therefor, and use thereof. In particular, the present invention relates to a pyrimidine-containing polycyclic compound or a st...
|
|
WO/2024/052513A1 |
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions contain...
|
